Compare GLU & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLU | GNLX |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.8M | 202.4M |
| IPO Year | N/A | 2023 |
| Metric | GLU | GNLX |
|---|---|---|
| Price | $19.31 | $3.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 12.4K | ★ 124.4K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.61 | $1.99 |
| 52 Week High | $15.40 | $8.54 |
| Indicator | GLU | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 60.65 | 28.22 |
| Support Level | $19.07 | $4.21 |
| Resistance Level | $20.13 | $4.99 |
| Average True Range (ATR) | 0.32 | 0.34 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 57.48 | 7.79 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.